Alnylam Pharmaceuticals | ALNY - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Arrowhead Research USD -141.26M 182.07M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.06B 521M 2025-12
PTC Therapeutics USD 45.89M 127.51M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.5B 2.29B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Takeda JPY -13.62B 182.44B 2026-03
Tectonic Therapeutic USD -21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Xencor USD -77.86M 24.23M 2026-03